# ENB Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enb-therapeutics

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.enbpharma.com
- Total disclosed funding: $2.3M
- Latest round: Series A (Sep 20, 2018)
- Investors on record: 4

## About

ENB Therapeutics, Inc. is an innovative biotechnology firm focused on developing therapies that target the tumor microenvironment to treat drug-resistant cancers.Founded in 2015 and headquartered in New York, US, ENB Therapeutics specializes in cancer therapies. The company has raised USD 2.29 mn in Series A funding led by Remiges Ventures, with participation from Alexandria Venture Investments, BioAdvance, and New York Ventures. Its latest deal occurred on September 20, 2018. Sumayah Jamal is the founder of ENB Therapeutics.ENB Therapeutics focuses on developing innovative therapies that target the tumor microenvironment, particularly for treating drug-resistant cancers. Their core products involve small molecules designed to inhibit the endothelin B receptor (ETBR), which plays a critical role in maintaining the 'cold' tumor phenotype by preventing immune cell infiltration. By turning off this receptor, ENB Therapeutics aims to create 'hot' tumors that allow immune cells to effectively attack cancer cells. The company’s lead compound, ENB-003, is currently in collaboration with Coherus Biosciences in clinical trials for ovarian cancer. The therapeutic solutions target a range of cancer types, including melanoma, glioblastoma, and squamous cell carcinoma, and demonstrate potential efficacy across various geographical markets, notably in North America and Europe.ENB Therapeutics generates revenue primarily through strategic partnerships and clinical collaborations with other biotechnology firms and research institutions. The company engages in B2B transactions, particularly through agreements that facilitate the development of their therapeutic products, such as ENB-003. These collaborations may involve milestone payments and royalties based on the successful advancement of drug candidates through clinical trials. The revenue structure is designed to capitalize on partnerships that enhance their product development pipeline and expand their market reach in oncology. Specific pricing plans or detailed financial arrangements related to their products and services have not been disclosed publicly.ENB Therapeutics plans to utilize the recent Series A funding of USD 2.29 mn raised in September 2018 to advance its pipeline of therapies and expand its market presence. The company is focused on the development of ENB-003 and aims to enhance its portfolio with new products targeting other oncology indications. Geographic expansion is also on the agenda, with a specific focus on increasing their market presence in Europe and North America. The strategic partnerships formed through recent funding rounds will further support their growth initiatives.

## Funding rounds

- Series A, Sep 20, 2018, $2.3M — Alexandria Venture Investments, BioAdvance, New York Ventures, Remiges Ventures

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- BioAdvance (https://capitalatlas.ai/funds/bioadvance) — Series A
- New York Ventures (https://capitalatlas.ai/funds/new-york-ventures) — Series A
- Remiges Ventures (https://capitalatlas.ai/funds/remiges-ventures) — Series A